{"id":59054,"date":"2026-03-09T12:27:26","date_gmt":"2026-03-09T04:27:26","guid":{"rendered":"https:\/\/flcube.com\/?p=59054"},"modified":"2026-03-09T12:27:27","modified_gmt":"2026-03-09T04:27:27","slug":"novo-nordisks-icosema-wins-nmpa-approval-once-weekly-insulin-semaglutide-combo-targets-china-type-2-diabetes-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=59054","title":{"rendered":"Novo Nordisk’s IcoSema Wins NMPA Approval \u2013 Once-Weekly Insulin-Semaglutide Combo Targets China Type 2 Diabetes Market"},"content":{"rendered":"\n

Novo Nordisk A\/S<\/strong> (NYSE: NVO<\/a>) secured NMPA approval<\/strong> for IcoSema<\/strong>, a once-weekly fixed-dose combination<\/strong> of insulin icodec<\/strong> and semaglutide<\/strong> for Type 2 diabetes<\/strong> treatment. The approval marks a significant expansion of Novo’s metabolic portfolio in China, combining the company’s long-acting basal insulin<\/strong> with the GLP-1 receptor agonist<\/strong> that powers blockbusters Ozempic<\/strong> and Wegovy<\/strong>, offering superior glycemic control with reduced hypoglycemia risk and weight benefits.<\/p>\n\n\n\n

Regulatory Milestone<\/h2>\n\n\n\n
Item<\/th>Detail<\/th><\/tr><\/thead>
Agency<\/strong><\/td>NMPA (China)<\/td><\/tr>
Approval Date<\/strong><\/td>March 2026 (week of 5\u202fMar)<\/td><\/tr>
Product<\/strong><\/td>IcoSema (insulin icodec + semaglutide)<\/td><\/tr>
Drug Class<\/strong><\/td>Once-weekly basal insulin\/GLP-1RA fixed-dose combination<\/td><\/tr>
Indication<\/strong><\/td>Type 2 diabetes<\/td><\/tr>
Components<\/strong><\/td>Insulin icodec (ultra-long-acting basal) + semaglutide 2.4\u202fmg (GLP-1RA)<\/td><\/tr>
Dosing Frequency<\/strong><\/td>Once-weekly subcutaneous injection vs. daily insulin regimens<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Clinical Evidence<\/h2>\n\n\n\n
Endpoint<\/th>IcoSema<\/th>Basal Insulin<\/th>Clinical Advantage<\/th><\/tr><\/thead>
HbA1c <7% Achievement<\/strong><\/td>72%<\/td>36%<\/td>2x higher glycemic target attainment<\/strong><\/td><\/tr>
Hypoglycemia Incidence<\/strong><\/td>Baseline<\/td>\u201378%<\/td>Superior safety profile<\/strong><\/td><\/tr>
“Quality” Metric<\/strong> (HbA1c <7% + no weight gain + no severe hypo)<\/td>55.7%<\/td>~11%<\/td>5x higher vs. basal insulin<\/strong><\/td><\/tr>
Weight Outcome<\/strong><\/td>Confirmed weight benefit<\/td>Weight gain typical<\/td>Metabolic advantage<\/strong><\/td><\/tr>
Cardiometabolic<\/strong><\/td>Improved waist circumference, BP, lipids<\/td>Less improvement<\/td>Broader metabolic benefits<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Patient Population:<\/strong> Adults with Type 2 diabetes previously treated with basal insulin<\/p>\n\n\n\n

Product Differentiation & Strategic Value<\/h2>\n\n\n\n
Attribute<\/th>IcoSema Advantage<\/th><\/tr><\/thead>
Convenience<\/strong><\/td>Once-weekly vs. daily injections (7x reduction in injection burden)<\/td><\/tr>
Adherence<\/strong><\/td>Simplified regimen addresses injection fatigue and compliance gaps<\/td><\/tr>
Efficacy<\/strong><\/td>Dual mechanism (insulin + GLP-1) targets fasting and post-prandial glucose<\/td><\/tr>
Safety<\/strong><\/td>78% hypoglycemia reduction addresses primary barrier to insulin intensification<\/td><\/tr>
Weight Profile<\/strong><\/td>Neutral\/positive weight effect vs. insulin-associated weight gain<\/td><\/tr>
Semaglutide Synergy<\/strong><\/td>Leverages proven GLP-1RA molecule with cardiovascular outcome data<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Market Impact & Commercial Strategy<\/h2>\n\n\n\n
Factor<\/th>Implication<\/th><\/tr><\/thead>
China T2D Market<\/strong><\/td>140+ million diagnosed patients; insulin intensification rates low due to complexity<\/td><\/tr>
Competitive Positioning<\/strong><\/td>First once-weekly insulin\/GLP-1 combo in China; challenges daily basal-bolus regimens<\/td><\/tr>
Pricing Power<\/strong><\/td>Premium positioning justified by adherence benefits and reduced complication costs<\/td><\/tr>
Portfolio Synergy<\/strong><\/td>Complements Ozempic (semaglutide monotherapy) and Wegovy (obesity) franchises<\/td><\/tr>
Launch Timeline<\/strong><\/td>Immediate availability; NRDL negotiation for 2026-2027 reimbursement<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Competitive Landscape<\/h2>\n\n\n\n
Competitor<\/th>Product<\/th>Mechanism<\/th>IcoSema Differentiation<\/th><\/tr><\/thead>
Sanofi<\/strong><\/td>Soliqua (insulin glargine + lixisenatide)<\/td>Daily basal insulin\/GLP-1<\/td>Once-weekly convenience advantage<\/td><\/tr>
Eli Lilly<\/strong><\/td>Mounjaro (tirzepatide)<\/td>Weekly GIP\/GLP-1 dual agonist<\/td>IcoSema includes insulin for advanced T2D<\/td><\/tr>
Novo Nordisk<\/strong><\/td>IcoSema<\/strong><\/td>Weekly insulin icodec + semaglutide<\/strong><\/td>First weekly insulin combo; semaglutide brand equity<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Forward\u2011Looking Statements<\/strong>
This brief contains forward\u2011looking statements regarding commercial launch performance, reimbursement negotiations, and market penetration for IcoSema in China. Actual results may differ due to competitive dynamics, pricing regulations, and patient adoption patterns.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Novo Nordisk A\/S (NYSE: NVO) secured NMPA approval for IcoSema, a once-weekly fixed-dose combination of…<\/p>\n","protected":false},"author":1,"featured_media":59058,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[39,4361,148,860,15],"class_list":["post-59054","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-diabetes","tag-hot-targets","tag-novo-nordisk","tag-nyse-nvo","tag-product-approvals"],"yoast_head":"\nNovo Nordisk's IcoSema Wins NMPA Approval \u2013 Once-Weekly Insulin-Semaglutide Combo Targets China Type 2 Diabetes Market - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk A\/S (NYSE: NVO) secured NMPA approval for IcoSema, a once-weekly fixed-dose combination of insulin icodec and semaglutide for Type 2 diabetes treatment. The approval marks a significant expansion of Novo's metabolic portfolio in China, combining the company's long-acting basal insulin with the GLP-1 receptor agonist that powers blockbusters Ozempic and Wegovy, offering superior glycemic control with reduced hypoglycemia risk and weight benefits.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=59054\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk's IcoSema Wins NMPA Approval \u2013 Once-Weekly Insulin-Semaglutide Combo Targets China Type 2 Diabetes Market\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk A\/S (NYSE: NVO) secured NMPA approval for IcoSema, a once-weekly fixed-dose combination of insulin icodec and semaglutide for Type 2 diabetes treatment. The approval marks a significant expansion of Novo's metabolic portfolio in China, combining the company's long-acting basal insulin with the GLP-1 receptor agonist that powers blockbusters Ozempic and Wegovy, offering superior glycemic control with reduced hypoglycemia risk and weight benefits.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=59054\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-09T04:27:26+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-09T04:27:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0901.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59054#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59054\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk’s IcoSema Wins NMPA Approval \u2013 Once-Weekly Insulin-Semaglutide Combo Targets China Type 2 Diabetes Market\",\"datePublished\":\"2026-03-09T04:27:26+00:00\",\"dateModified\":\"2026-03-09T04:27:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59054\"},\"wordCount\":421,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59054#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0901.webp\",\"keywords\":[\"Diabetes\",\"Hot targets\",\"Novo Nordisk\",\"NYSE: NVO\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59054#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59054\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=59054\",\"name\":\"Novo Nordisk's IcoSema Wins NMPA Approval \u2013 Once-Weekly Insulin-Semaglutide Combo Targets China Type 2 Diabetes Market - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59054#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59054#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0901.webp\",\"datePublished\":\"2026-03-09T04:27:26+00:00\",\"dateModified\":\"2026-03-09T04:27:27+00:00\",\"description\":\"Novo Nordisk A\\\/S (NYSE: NVO) secured NMPA approval for IcoSema, a once-weekly fixed-dose combination of insulin icodec and semaglutide for Type 2 diabetes treatment. The approval marks a significant expansion of Novo's metabolic portfolio in China, combining the company's long-acting basal insulin with the GLP-1 receptor agonist that powers blockbusters Ozempic and Wegovy, offering superior glycemic control with reduced hypoglycemia risk and weight benefits.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59054#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=59054\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59054#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0901.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0901.webp\",\"width\":1080,\"height\":608,\"caption\":\"Novo Nordisk's IcoSema Wins NMPA Approval \u2013 Once-Weekly Insulin-Semaglutide Combo Targets China Type 2 Diabetes Market\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=59054#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk’s IcoSema Wins NMPA Approval \u2013 Once-Weekly Insulin-Semaglutide Combo Targets China Type 2 Diabetes Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk's IcoSema Wins NMPA Approval \u2013 Once-Weekly Insulin-Semaglutide Combo Targets China Type 2 Diabetes Market - Insight, China's Pharmaceutical Industry","description":"Novo Nordisk A\/S (NYSE: NVO) secured NMPA approval for IcoSema, a once-weekly fixed-dose combination of insulin icodec and semaglutide for Type 2 diabetes treatment. The approval marks a significant expansion of Novo's metabolic portfolio in China, combining the company's long-acting basal insulin with the GLP-1 receptor agonist that powers blockbusters Ozempic and Wegovy, offering superior glycemic control with reduced hypoglycemia risk and weight benefits.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=59054","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk's IcoSema Wins NMPA Approval \u2013 Once-Weekly Insulin-Semaglutide Combo Targets China Type 2 Diabetes Market","og_description":"Novo Nordisk A\/S (NYSE: NVO) secured NMPA approval for IcoSema, a once-weekly fixed-dose combination of insulin icodec and semaglutide for Type 2 diabetes treatment. The approval marks a significant expansion of Novo's metabolic portfolio in China, combining the company's long-acting basal insulin with the GLP-1 receptor agonist that powers blockbusters Ozempic and Wegovy, offering superior glycemic control with reduced hypoglycemia risk and weight benefits.","og_url":"https:\/\/flcube.com\/?p=59054","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-09T04:27:26+00:00","article_modified_time":"2026-03-09T04:27:27+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0901.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=59054#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=59054"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk’s IcoSema Wins NMPA Approval \u2013 Once-Weekly Insulin-Semaglutide Combo Targets China Type 2 Diabetes Market","datePublished":"2026-03-09T04:27:26+00:00","dateModified":"2026-03-09T04:27:27+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=59054"},"wordCount":421,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=59054#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0901.webp","keywords":["Diabetes","Hot targets","Novo Nordisk","NYSE: NVO","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=59054#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=59054","url":"https:\/\/flcube.com\/?p=59054","name":"Novo Nordisk's IcoSema Wins NMPA Approval \u2013 Once-Weekly Insulin-Semaglutide Combo Targets China Type 2 Diabetes Market - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=59054#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=59054#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0901.webp","datePublished":"2026-03-09T04:27:26+00:00","dateModified":"2026-03-09T04:27:27+00:00","description":"Novo Nordisk A\/S (NYSE: NVO) secured NMPA approval for IcoSema, a once-weekly fixed-dose combination of insulin icodec and semaglutide for Type 2 diabetes treatment. The approval marks a significant expansion of Novo's metabolic portfolio in China, combining the company's long-acting basal insulin with the GLP-1 receptor agonist that powers blockbusters Ozempic and Wegovy, offering superior glycemic control with reduced hypoglycemia risk and weight benefits.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=59054#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=59054"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=59054#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0901.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0901.webp","width":1080,"height":608,"caption":"Novo Nordisk's IcoSema Wins NMPA Approval \u2013 Once-Weekly Insulin-Semaglutide Combo Targets China Type 2 Diabetes Market"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=59054#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk’s IcoSema Wins NMPA Approval \u2013 Once-Weekly Insulin-Semaglutide Combo Targets China Type 2 Diabetes Market"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0901.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59054","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=59054"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59054\/revisions"}],"predecessor-version":[{"id":59059,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/59054\/revisions\/59059"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/59058"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=59054"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=59054"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=59054"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}